Dov Bergwerk, Senior Vice President, General Counsel, and Corporate Secretary of Teva Pharmaceutical Industries Ltd, filed a Form 144 notice of proposed sale of 26,260 ordinary shares on November 4, 2026, through a stock option exercise and sale transaction on the NYSE.
Key Highlights
- Filer and role: Dov Bergwerk, Senior VP General Counsel Corporate Secretary of Teva Pharmaceutical Industries Ltd
- Shares proposed for sale: 26,260 ordinary shares
- Aggregate market value: $1,095,567.20
- Acquisition type: Stock option exercise and sale, acquired from Teva Pharmaceutical Industries Limited on November 4, 2026
- Indicative market price: $41.72 per share, as stated in the filing's remarks section
- Broker named: Citigroup Global Markets, Inc., 390 Greenwich St, New York, NY 10013
- No securities sold in past 3 months: The filing reports nothing to report under the prior three-month sales section
Bergwerk's Proposed Option Exercise and Sale at Teva Pharmaceutical
According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 4, 2026, Dov Bergwerk, who serves as Senior VP General Counsel and Corporate Secretary of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), provided notice of a proposed sale of 26,260 ordinary shares. The filing states the nature of the acquisition transaction as a "STOCK OPTION EXERCISE AND SALE," with the shares acquired from Teva Pharmaceutical Industries Limited on November 4, 2026, with payment made in cash on the same date.
The filing reports an aggregate market value of $1,095,567.20 for the shares proposed to be sold, against a total of 1,166,826,784 ordinary shares outstanding, according to the disclosure. The remarks section of the filing states: "SHARES SOLD PURSUANT TO STOCK OPTION EXERCISE AND SALE TRANSACTION. UNDER SECTION 3D INDICATIVE MARKET PRICE WAS 41.72." The proposed sale is to be executed on the NYSE through Citigroup Global Markets, Inc.
The filing further discloses that Bergwerk had no securities of Teva sold during the prior three months, with the form indicating "Nothing to Report" for that section. The filer's conformed signature is on file with the SEC. The filing carries the standard Form 144 representation that the person signing "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."
What Was Disclosed
Teva Pharmaceutical's General Counsel Dov Bergwerk filed a Form 144 on November 4, 2026, disclosing a proposed sale of 26,260 ordinary shares with an aggregate market value of $1,095,567.20, acquired via a stock option exercise and to be sold on the NYSE.




Please wait processing your request...